Abbott to obtain Action Pharma’s Investigational Substance, AP214 Abbott and Action Pharma A/S, a privately owned company, announced they have entered into an agreement where Abbott shall acquire AP214 from Action Pharma. AP214 is normally in development to prevent acute kidney injury associated with major cardiac surgery in patients at elevated risk and has additional potential in adjacent indications cognition-enhancing drugs . AP214 is certainly a hormone analogue that targets both systemic irritation and cellular death caused by hypoxia that may occur during surgery. In September 2011, Actions Pharma announced positive Stage 2b top-line outcomes evaluating the efficacy, protection and tolerability of AP214. Abbott plans to conduct another Phase 2b study, which is expected to begin later this season.
‘Put simply, by directing the way people move their bodies, we are – unbeknownst to them – directing the way they think about the problem.’ Even after effectively solving the problem, almost none of the analysis subjects became consciously aware of any connection between your physical activity they involved in and the solution they found. ‘The results are interesting both because body movement can affect higher order thought, the complicated thinking had a need to solve complicated complications, and because this effect occurs even when someone else is directing the actions of the individual trying to solve the issue,’ Lleras said.